首页 国际期刊 医学期刊 期刊详情(非官网)
400-808-1701

Breast Cancer

Breast Cancer杂志,由Springer Japan出版,于1994年创刊,6 issues per year,出版语言English,ISSN:1340-6868,E-ISSN:1880-4233。

投稿咨询
Breast Cancer
Breast Cancer
Breast Cancer
SCI SCIE

杂志介绍

JCR分区
Q1
中科院分区
3区
影响因子
3.7
CiteScore
5.4
期刊收录
SCI、SCIE

Breast Cancer(中文译名:《乳腺癌》),ISSN:1340-6868,EISSN:1880-4233,是Springer Japan出版的国际性学术期刊,创刊于1994年,以6 issues per year形式稳定发行,2026年总发文量约131篇。该刊采用非OA开放访问,学科归属为ONCOLOGY - OBSTETRICS & GYNECOLOGY。该刊是医学、肿瘤学领域的国际权威刊物,已被SCI(科学引文索引)、SCIE(科学引文索引扩展版)等国际主流学术数据库收录。2026年期刊影响因子达3.7,2025年期刊CiteScore为5.4,2025年期刊自引率约8.1%,在中科院期刊分区体系中位列医学大类3区,在所属学科领域具备高学术影响力与国际认可度。Breast Cancer长期聚焦医学、肿瘤学及相关产业的技术应用前沿,平均审稿周期较慢,6-12周,审稿流程高效稳定。在稿件录用评判中,该刊将创新性与前沿性作为核心遴选标准,重点收录能够对医学、肿瘤学领域的落地与发展产生实质性推动价值的研究成果。

从全球发文格局来看,JapanCHINA MAINLAND、USA、Turkey、England、Iran、Italy等为核心发文国家与地区;JAPANESE FOUNDATION FOR CANCER RESEARCHAICHI CANCER CENTER、NATIONAL CANCER CENTER - JAPAN、KYOTO UNIVERSITY、TOHOKU UNIVERSITY、ST. LUKE'S INTERNATIONAL HOSPITAL、SHOWA UNIVERSITY等高校与科研机构是期刊的主要发文单位。

期刊评价

名词解释:

影响因子(Impact Factor, IF):指该期刊前两年发表的文章,在第三年的平均被引用次数。它反映了期刊的近期平均影响力和热度。

中科院分区:中科院分区表是国内主流的学术期刊分级评价工具,核心意义是建立跨学科可比的统一评价标尺,为职称评审、学位授予、科研立项等科研管理工作提供标准化量化依据,同时帮助科研人员筛选优质期刊、规避学术风险,适配国内本土化的科研评价需求。

期刊分区表

《新锐期刊分区表》(2026年3月发布)

大类学科 小类学科 Top期刊 综述期刊
医学
3区
ONCOLOGY 肿瘤学 OBSTETRICS & GYNECOLOGY 妇产科学
3区 3区

期刊分区表(2025年3月升级版)

大类学科 小类学科 Top期刊 综述期刊
医学
3区
OBSTETRICS & GYNECOLOGY 妇产科学 ONCOLOGY 肿瘤学
3区 4区

期刊分区表(2022年12月升级版)

大类学科 小类学科 Top期刊 综述期刊
医学
3区
OBSTETRICS & GYNECOLOGY 妇产科学 ONCOLOGY 肿瘤学
3区 4区

JCR分区

2025-2026年最新版

按JCI指标学科分区 收录子集 分区 排名 百分位
学科:OBSTETRICS & GYNECOLOGY SCIE Q1 21 / 143

85.7

学科:ONCOLOGY SCIE Q2 129 / 333

61.4

学科:OBSTETRICS & GYNECOLOGY SCIE Q2 36 / 143

75.17

学科:ONCOLOGY SCIE Q2 91 / 333

72.82

2023-2024年最新版

按JCI指标学科分区 收录子集 分区 排名 百分位
学科:OBSTETRICS & GYNECOLOGY SCIE Q1 14 / 136

90.1

学科:ONCOLOGY SCIE Q2 95 / 322

70.7

学科:OBSTETRICS & GYNECOLOGY SCIE Q2 39 / 136

71.69

学科:ONCOLOGY SCIE Q2 87 / 322

73.14


中国学者近期发文

1
Solamargin-functionalized gold nanoparticles codelivering photothermal-immunotherapy for triple-negative breast cance

Author:Gui, Zhengwei; Zhao, Lu; Liu, Shiyang; Zhang, Lin

Journal: BREAST CANCER. 2026; Vol. 33, Issue 3, pp. 705-721. DOI: 10.1007/s12282-026-01849-0

2
Beyond the triad: biological subtypes and the safety net in omitting sentinel lymph node biops

Author:Ye, Bin; Ma, Bo

Journal: BREAST CANCER. 2026; Vol. 33, Issue 3, pp. 798-799. DOI: 10.1007/s12282-026-01848-1

3
Time-dependent diffusion MRI for non-invasive differentiation of benign and malignant breast lesions and evaluation of proliferation index biomarker

Author:Ru, Luqing; Tang, Yanlin; Zhang, Jigeng; Shi, Ran; Yin, Dawei; Zhang, Yong; Kong, Yuan; Du, Jun; Wang, Peng

Journal: BREAST CANCER. 2026; Vol. , Issue , pp. -. DOI: 10.1007/s12282-026-01842-7

4
Evaluating high-risk breast cancer surveillance outcomes in BRCA mutation carrier

Author:Chang, Yuk-Kwan; Luk, Wing-Pan; Fung, Ling-Hiu; Kwong, Ava

Journal: BREAST CANCER. 2026; Vol. , Issue , pp. -. DOI: 10.1007/s12282-026-01822-x

5
Exploring a specialized lactylation pattern to predict the prognosis and sensitivity of immunotherapy in breast cancer via machine learnin

Author:Li, Lin; Wang, Mingrui; Li, Xin; Ding, Jinhua

Journal: BREAST CANCER. 2026; Vol. , Issue , pp. -. DOI: 10.1007/s12282-026-01829-4

6
FGFR4 and HER2 co-expression is associated with the proinflammatory tumor microenvironment in HR plus breast cance

Author:Gao, Yike; Chen, Longyun; Yao, Fei; Wang, Jin; Zhu, Changbin; Wu, Shafei; Liang, Zhiyong

Journal: BREAST CANCER. 2026; Vol. , Issue , pp. -. DOI: 10.1007/s12282-026-01833-8

7
Prognostic model for pulmonary metastasis in patients with HER2-positive breast cancer: a population-based stud

Author:Pang, Jun; Huang, Bingbing; Yan, Wanying; He, Huijun; Liao, Nvzhu; Sun, Wenna; Li, Yaoquan; Luo, Lishan; Zeng, Wei

Journal: BREAST CANCER. 2026; Vol. , Issue , pp. -. DOI: 10.1007/s12282-026-01836-5

8
Reevaluating ALND omission and its impact on abemaciclib eligibility and treatment decision

Author:Ren, Shi-Yan; Zhang, Yi-Zhou

Journal: BREAST CANCER. 2025; Vol. , Issue , pp. -. DOI: 10.1007/s12282-025-01727-1

9
Clinical application of 90-gene expression test in a patient with occult breast cancer: a case report and literature revie

Author:Xu, Guojie; Zhao, Kewei; Zhou, Xi; Zhang, Liling; Liu, Jiaying; Zhao, Yanxia; Han, Dan

Journal: BREAST CANCER. 2025; Vol. , Issue , pp. -. DOI: 10.1007/s12282-025-01728-0

10
Treatment and prognosis of patients with hormone receptor-low positive (1%-10%) breast cancer: a retrospective propensity score-matched analysi

Author:Luo, Yulou; Saibaidula, Yilina; Sun, Yutian; Ye, Yinghui; Ou, Jianghua

Journal: BREAST CANCER. 2025; Vol. , Issue , pp. -. DOI: 10.1007/s12282-025-01730-6


在线咨询

Breast Cancer

国际简称:BREAST CANCER-TOKYO参考译名:乳腺癌

年发文量:131 CiteScore:5.4 是否预警:否 Gold OA文章占比:41.55% 研究类文章占比:89.31%

杂志社联系方式:SHIROYAMA TRUST TOWER 5F, 4-3-1 TORANOMON, MINATO-KU, TOKYO, JAPAN, 105-6005

Breast Cancer